DMAC Earnings Date: Nov 11, 2026 (Estimated) — DiaMedica Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is DMAC's next earnings date?
DiaMedica Therapeutics Inc. (DMAC) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.20 on revenue of $13.5M.
How did DMAC do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), DiaMedica Therapeutics Inc. posted EPS of -$0.19 versus the -$0.20 estimate, a beat of 5.0%. Revenue was $0 against a $13.5M estimate. The stock's 1-day post-earnings move was +3.3%.
How much does DMAC stock move after earnings?
DMAC beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.20 | -0.19 | +5.00% | $0 | ✅ Beat | +3.31% | -0.45% | -0.90% |
| 2026-05-06 | Q1 2026 | -0.18 | -0.19 | -5.56% | $0 | ❌ Miss | +0.15% | -3.99% | -13.50% |
| 2026-03-30 | Q4 2025 | -0.18 | -0.17 | +5.56% | $0 | ✅ Beat | +1.96% | -1.36% | -10.24% |
| 2025-11-12 | Q3 2025 | -0.16 | -0.17 | -6.25% | $0 | ❌ Miss | -14.10% | +15.69% | +48.81% |
| 2025-08-12 | Q2 2025 | -0.19 | -0.18 | +5.26% | $0 | ✅ Beat | +14.94% | +10.54% | +39.46% |
| 2025-03-17 | Q4 2024 | -0.17 | -0.18 | -5.88% | $0 | ❌ Miss | -13.02% | -17.36% | -41.40% |
| 2024-11-13 | Q3 2024 | -0.15 | -0.15 | +0.00% | $0 | ➖ Inline | -3.29% | -5.63% | +26.29% |
| 2024-08-07 | Q2 2024 | -0.16 | -0.13 | +18.75% | $0 | ✅ Beat | +3.08% | +7.08% | +24.00% |
Showing last 8 quarters.